Association between salivary and serum Interleukin-39 and osteopontin in periodontitis patients: case-control study
Main Article Content
Abstract
Background: Cytokines have a crucial role in developing chronic inflammation and the inflammatory response. Some interleukins, such as interleukin-39 (IL-39), have unknown specific roles in the pathogenesis of periodontitis. Osteopontin has been shown to be a multifunctional cytokine and a unique modulator of innate and adaptive immune responses. Therefore, the study's objective was to measure IL-39 and osteopontin level and their ratio in the saliva and serum of periodontitis patients in Iraq. Materials and methods: This case-control study include 78 individuals with an age range of 25-60 years (40 periodontitis patients without clinical intervention and 38 healthy volunteers). Levels of salivary, serum IL-39 and osteopontin were determined for both groups, utilizing the Enzyme-Linked Immunosorbent Assay technique. The Social Science Statistical Package (Version 26; SPSS, IBM) was utilized for statistical analysis. Results: Serum levels of IL-39 and osteopontin were significantly elevated in periodontitis patients compared to healthy participants (p < 0.001 and p = 0.001, respectively). A similar pattern was observed in saliva, with significantly higher levels of IL-39 and OPN in periodontitis patients. Positive correlations were detected between serum and salivary levels of IL-39 (p = 0.037) and OPN (p = 0.003). Diagnostic validity tests demonstrated that IL-39 and OPN assays exhibited high sensitivity and negative predictive value (100%), and high accuracy (94.87% to 100%). The area under the curve values approached 1.0. Conclusion: Elevated saliva interleukin-39 and Osteopontin levels and elevated serum parameters are strongly associated with periodontitis.
Received date: 01-07-2024
Accepted date: 02-09-2024
Published date: 15-09-2025
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Imran NK, Abdulbaqi HR, Milward M. The prevalence of periodontitis in an Iraqi population using the 2017 classification. J Bagh Coll Dent. 2024;36(2):1-10.
Bezerra B, Monajemzadeh S, Silva D, Pirih FQ.. Modulating the immune response in periodontitis. Front Dent Med. 2022: 879131.
Parmar NK NK, Guru S, Padmanabhan S. Role of matrixmetalloproteinases in periodontal disease-A review. Biomed J Sci Tech Res.2018;2(1): 2099-104.
Al-Daragi FZ, Al-Ghurabi BH, Abdullah NN. Serum levels of antimicrobial peptides (Cathelicidins and Beta Defensins-1) in patients with periodontitis. J Bagh Coll Dent. 2024; 36(1):9_18.
Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J Oral Microbiol. 2011;3(1):5304.
Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Rese. 2018;38(10):423-39.
Arya A, Aswathy J, Mohan Aswathy K, Chinchu JA, Deepa M. Interleukin-6 in oral health and diseases. President’s Message. 2017;7(2):52.
Li X, Liu X, Wang W. IL-35: a novel immunomodulator in hepatitis B virus-related liver diseases. Front Cell Develop Biol. 2021;9:614847.
Ismail HS, Mahmood MS. Effect of melatonin supplementation on the gingival health and lipid profiles in obese periodontitis patients. J Bagh Coll Dent. 2022;34(1):51-9.
Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci. 2017;11(2):72-80.
Van Dyke TE, Sheilesh D. Risk factors for periodontitis. J Int Acad Periodontol. 2005;7(1):3-7.
Dowsett SA, Archila L, Segreto VA, Eckert GJ, Kowolik MJ. Periodontal disease status of an indigenous population of Guatemala, Central America.J Clin Periodentol. 2001;28(7):663-71.
Ullrich KA, Schulze LL, Paap EM, Müller TM, Neurath MF, Zundler S. Immunology of IL-12: An update on functional activities and implications for disease. EXCLI J. 2020;19:1563-89.
Mohammed WT, Alosami MHM, Alubadi AEM. An assessment of serum interleukin-39 in rheumatoid arthritis patients from Iraq. Biomedicine. 2022;42(4):699-702.
Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers. 2021;13(2):167.
Lu Z, Xu K, Wang X, Li Y, Li M. Interleukin 39: a new member of interleukin 12 family. Cent Eur J Immunol. 2020;45(2):214-7.
Li Y, Gong L, Weng L, Pan X, Liu C, Li M. Interleukin-39 exacerbates concanavalin A-induced liver injury. Immunopharmacol Immunotoxicol. 2021;43(1):94-9.
Zahra’a AA, Alrawi PAA. Evaluation of IL-35 and IL-39 in Rheumatoid Arthritis. J Fac Med Bagh. 2022;64(3).
Si J, Wang C, Zhang D, Wang B, Hou W, Zhou Y. Osteopontin in bone metabolism and bone diseases. Med Sci Monit 2020; 26:e919159.
Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5-6):333-45..
Lin EY, Xi W, Aggarwal N, Shinohara ML. Osteopontin (OPN)/SPP1: from its biochemistry to biological functions in the innate immune system and the central nervous system (CNS). Int Immunol. 2023;35(2):171-180.
Del Prete A, Scutera S, Sozzani S, Musso T. Role of osteopontin in dendritic cell shaping of immune responses. Cytokine Growth Factor Rev. 2019;50:19-28.
Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, et al. Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells. Nature immunol. 2006;7(5):498-506.
Sharma CD, Pradeep A. Gingival crevicular fluid osteopontin levels in periodontal health and disease. J Periodontol. 2006;77(10):1674-80.
Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17-24.
Nussrat SW, Ad'hiah AH. Interleukin‐39 is a novel cytokine associated with type 2 diabetes mellitus and positively correlated with body mass index. Endocr Metab. 2023;6(3):e409.
Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers. 2021 Jan 6;13(2):167.
Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int J Molec Sci. 2022;23(5):2871.
Sari A, Dogan S, Nibali L, Koseoglu S. Evaluation of IL-23p19/Ebi3 (IL-39) gingival crevicular fluid levels in periodontal health, gingivitis, and periodontitis. Clin Oral Investig. 2022;26(12):7209-18.
Hassan SS, Abdelkawy M, Shaker OG, Tarrad NAF. IL-39 and IL-35 gingival crevicular fluid levels in diabetic patients with generalized periodontitis. Clin Oral Investig. 2024;28(2):124.
Al-Qarakhli A, Al-Taweel F, Abdul Ameer L, Saliem S, Abdulkareem A. Assessing the Level and Diagnostic Accuracy of Osteopontin and Oral Health Status in Periodontitis Patients with/without Type-2 Diabetes Mellitus. Braz Dent Sci. 2022;24.
Ram VS, Sudhakar U, Mithradas N, Prabhakar R. Bonebiomarkers in periodontal disease: a review article. J Clin Diagn Res. 2015;9(1):ZE07.
Patil PB, Patil BR. Saliva: A diagnostic biomarker of periodontal diseases. J Indian Soc Periodontol. 2011;15(4):310-7..
Taba M Jr, Kinney J, Kim AS, Giannobile WV. Diagnostic biomarkers for oral and periodontal diseases. Dent Clin North Am. 2005 Jul;49(3):551-71, vi.
Hans S, Mali AM. Estimation and comparison of osteopontin levels in plasma in subjects with healthy periodontium and generalized chronic periodontitis and its assessment after scaling and root planing. J Indian Soc Periodontol. 2012;16(3):354-7.
Dong M, Yu X, Chen W, Guo Z, Sui L, Xu Y, et al. Osteopontin Promotes Bone Destruction in Periapical Periodontitis by Activating the NF-κB Pathway. Cell Physiol Biochem. 2018;49(3):884-98.
Sharma C, Pradeep A. Plasma and crevicular fluid osteopontin levels in periodontal health and disease. J Periodontal Res. 2007;42(5):450-5.
Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Ann N Y Acad Sci. 2007;1098:230-51.
Ali Alftaikhah SA, Issrani R, Alnasser M, Almutairi HA, Khattak O, Iqbal A, et al. Salivary Biomarkers in Periodontitis: A Scoping Review. Cureus. 2023;15(12):e50207.
Lee KT, Guo ZL, Teng NC, Hsu KC, Chen IH, Lee CY, et al. Salivary Pro-Inflammatory Markers and Smoking Status Influences the Treatment Effectiveness of Periodontal Disease Patients with Hypertension. Int J Environ Res Public Health. 2021;18(14)..